<DOC>
	<DOCNO>NCT00824980</DOCNO>
	<brief_summary>The major objective study evaluate therapeutic effect topical treatment simultaneously inhibit Dipeptidyl Peptidase IV Aminopeptidase N ( IMTM # IP10.C8 ) patient mild moderate psoriasis skin</brief_summary>
	<brief_title>Combined Inhibition Dipeptidyl Peptidase IV ( DPIV/CD26 ) Aminopeptidase N ( APN/CD13 ) Treatment Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Age 18 year age prestudy 2 . Diagnosis plaque type psoriasis least 3 month prior enrolment 3 . Mild moderate plaque type psoriasis least 2 plaque approximately 15cm2 topical treatment indicate 4 . Patients must able give write informed consent trialspecific procedure perform ( see Section 12.2 1 . Other type psoriasis ( e.g . erythrodermic , guttate pustular ) enrolment 2 . Drug induce psoriasis enrolment ( e.g . lithium ) 3 . Pregnant lactate woman , patient ( men woman ) plan pregnancy duration study 4 . Systemic therapy affect PASI phototherapy period 4 week prior enrolment 5 . Topical therapy affect PASI period 2 week prior enrolment 6 . Treatment biologic agent affect PASI period 3 month prior enrolment 7 . Systemic treatment immunosuppressive agent ( e.g . methotrexate , cyclosporin ) treatment lithium , antimalaria medication , intramuscular gold application period 4 week prior enrolment 8 . Having history ongoing uncontrolled serious recur bacterial , viral , fungal , atypical mycobacterial infection 9 . Having severe medical condition , judgment investigator , would jeopardize way subject 's safety follow exposure study drug 10 . Having presence history malignancy , include lymphoproliferative disorder . Subjects history fully resolve basal squamous cell skin cancer may enrol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>